Lupus nephritis: Maintenance therapy for lupus nephritis-do we now have a plan?

Oliver Lenz, Ahmed A. Waheed, Abdur Baig, Alexander Pop, Gabriel Contreras

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Lupus nephritis (LN) increases the morbidity and mortality of patients with SLE. This review compares the randomized, controlled trials that examined various maintenance regimens available to treat LN. Currently, mycophenolate mofetil (MMF) and azathioprine (AZA) are the most popular therapeutic agents used for long-term maintenance of LN. Long-term maintenance with MMF is recommended as the first choice after achieving remission with cyclophosphamide or MMF induction. MMF is effective in consolidating remission and preventing relapse and CKD in patients of diverse races and ethnicities. Long-term maintenance with AZA is the recommended second choice, especially when patients develop intolerance of or contraindications to MMF. Azathioprine is particularly effective in consolidating remission and preventing relapse and CKD in patients who receive an induction regimen of cyclophosphamide. To date, there are no data on how rapidly maintenance therapies can be withdrawn; however, it is recommended that the immunosuppressive therapy be maintained indefinitely, unless it is contraindicated, in patients at high risk for progression to CKD.

Original languageEnglish
Pages (from-to)162-171
Number of pages10
JournalClinical Journal of the American Society of Nephrology
Volume8
Issue number1
DOIs
StatePublished - Jan 7 2013

Fingerprint

Mycophenolic Acid
Lupus Nephritis
Azathioprine
Cyclophosphamide
Therapeutics
Recurrence
Immunosuppressive Agents
Randomized Controlled Trials
Maintenance
Morbidity
Mortality

ASJC Scopus subject areas

  • Nephrology
  • Transplantation
  • Epidemiology
  • Critical Care and Intensive Care Medicine

Cite this

Lupus nephritis : Maintenance therapy for lupus nephritis-do we now have a plan? / Lenz, Oliver; Waheed, Ahmed A.; Baig, Abdur; Pop, Alexander; Contreras, Gabriel.

In: Clinical Journal of the American Society of Nephrology, Vol. 8, No. 1, 07.01.2013, p. 162-171.

Research output: Contribution to journalArticle

@article{6b6fc94a709541a0b55dfdb49654d005,
title = "Lupus nephritis: Maintenance therapy for lupus nephritis-do we now have a plan?",
abstract = "Lupus nephritis (LN) increases the morbidity and mortality of patients with SLE. This review compares the randomized, controlled trials that examined various maintenance regimens available to treat LN. Currently, mycophenolate mofetil (MMF) and azathioprine (AZA) are the most popular therapeutic agents used for long-term maintenance of LN. Long-term maintenance with MMF is recommended as the first choice after achieving remission with cyclophosphamide or MMF induction. MMF is effective in consolidating remission and preventing relapse and CKD in patients of diverse races and ethnicities. Long-term maintenance with AZA is the recommended second choice, especially when patients develop intolerance of or contraindications to MMF. Azathioprine is particularly effective in consolidating remission and preventing relapse and CKD in patients who receive an induction regimen of cyclophosphamide. To date, there are no data on how rapidly maintenance therapies can be withdrawn; however, it is recommended that the immunosuppressive therapy be maintained indefinitely, unless it is contraindicated, in patients at high risk for progression to CKD.",
author = "Oliver Lenz and Waheed, {Ahmed A.} and Abdur Baig and Alexander Pop and Gabriel Contreras",
year = "2013",
month = "1",
day = "7",
doi = "10.2215/CJN.03640412",
language = "English",
volume = "8",
pages = "162--171",
journal = "Clinical journal of the American Society of Nephrology : CJASN",
issn = "1555-9041",
publisher = "American Society of Nephrology",
number = "1",

}

TY - JOUR

T1 - Lupus nephritis

T2 - Maintenance therapy for lupus nephritis-do we now have a plan?

AU - Lenz, Oliver

AU - Waheed, Ahmed A.

AU - Baig, Abdur

AU - Pop, Alexander

AU - Contreras, Gabriel

PY - 2013/1/7

Y1 - 2013/1/7

N2 - Lupus nephritis (LN) increases the morbidity and mortality of patients with SLE. This review compares the randomized, controlled trials that examined various maintenance regimens available to treat LN. Currently, mycophenolate mofetil (MMF) and azathioprine (AZA) are the most popular therapeutic agents used for long-term maintenance of LN. Long-term maintenance with MMF is recommended as the first choice after achieving remission with cyclophosphamide or MMF induction. MMF is effective in consolidating remission and preventing relapse and CKD in patients of diverse races and ethnicities. Long-term maintenance with AZA is the recommended second choice, especially when patients develop intolerance of or contraindications to MMF. Azathioprine is particularly effective in consolidating remission and preventing relapse and CKD in patients who receive an induction regimen of cyclophosphamide. To date, there are no data on how rapidly maintenance therapies can be withdrawn; however, it is recommended that the immunosuppressive therapy be maintained indefinitely, unless it is contraindicated, in patients at high risk for progression to CKD.

AB - Lupus nephritis (LN) increases the morbidity and mortality of patients with SLE. This review compares the randomized, controlled trials that examined various maintenance regimens available to treat LN. Currently, mycophenolate mofetil (MMF) and azathioprine (AZA) are the most popular therapeutic agents used for long-term maintenance of LN. Long-term maintenance with MMF is recommended as the first choice after achieving remission with cyclophosphamide or MMF induction. MMF is effective in consolidating remission and preventing relapse and CKD in patients of diverse races and ethnicities. Long-term maintenance with AZA is the recommended second choice, especially when patients develop intolerance of or contraindications to MMF. Azathioprine is particularly effective in consolidating remission and preventing relapse and CKD in patients who receive an induction regimen of cyclophosphamide. To date, there are no data on how rapidly maintenance therapies can be withdrawn; however, it is recommended that the immunosuppressive therapy be maintained indefinitely, unless it is contraindicated, in patients at high risk for progression to CKD.

UR - http://www.scopus.com/inward/record.url?scp=84872194487&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872194487&partnerID=8YFLogxK

U2 - 10.2215/CJN.03640412

DO - 10.2215/CJN.03640412

M3 - Article

C2 - 22917704

AN - SCOPUS:84872194487

VL - 8

SP - 162

EP - 171

JO - Clinical journal of the American Society of Nephrology : CJASN

JF - Clinical journal of the American Society of Nephrology : CJASN

SN - 1555-9041

IS - 1

ER -